Real-world immunotherapy for newly diagnosed multiple myeloma
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how well first-line immunotherapy works for people newly diagnosed with multiple myeloma in real-world clinical settings in China. The goal is to understand what treatments are used and how patients respond.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with multiple myeloma.
- You plan to start your first cancer treatment with immunotherapy at the hospital where this study is being done.
- Your first treatment includes a proteasome inhibitor (like bortezomib), an immunomodulatory drug (like lenalidomide), or an anti-CD38 antibody (like daratumumab), alone or together with other medicines.
- You are 18 years old or older.
- You are able to understand the study and agree to take part by signing a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called RN1201 as a first-line treatment for multiple myeloma, a blood cancer. The study aims to see if it is safe and effective for patients who have never been treated for this condition before.
This trial tests whether a new medicine (AZD0120) can work as well or better than a stem cell transplant for people with newly diagnosed multiple myeloma who have already finished initial treatment. It might help avoid the need for a transplant.
This study uses a special imaging test called a PET scan to learn more about multiple myeloma and how it responds to treatment. The results may help doctors better predict outcomes and tailor care for people with newly diagnosed disease.
This trial tests a new drug called CM336 for people with multiple myeloma that has come back or stopped responding to at least two previous treatments. It aims to see if CM336 can help control the disease.
This trial tests a new drug, BMS-986453, for people newly diagnosed with multiple myeloma. It aims to see if the drug is safe and works well for those who cannot or choose not to have a stem cell transplant.
This trial tests a type of immune therapy called bispecific T-cell redirectors combined with standard medicines for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if this treatment helps control the cancer better.
Hear when a new Newly Diagnosed Multiple Myeloma (NDMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.